研究单位:[1]Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.[2]Tianjin Medical University Cancer Institute and Hospital[3]The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital河北医科大学第四医院[4]Second Affiliated Hospital of Nanchang University[5]Guangdong Provincial People's Hospital
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes